Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
about
Management of HBV and HBV/HDV-Associated Liver CirrhosisKASL clinical practice guidelines: management of chronic hepatitis BUpdate on Hepatitis B Virus Infection: Focus on TreatmentHepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawalOutcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factorsTreatment for hepatitis B in patients with drug resistanceHepatitis B virus and its sexually transmitted infection - an update.Current hepatitis B treatment guidelines and future research directions.The Role of cccDNA in HBV Maintenance.Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL.AASLD guidelines for treatment of chronic hepatitis B.Personalized treatment of hepatitis B.Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis.AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B.Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis BSimple and Reliable Method to Quantify the Hepatitis B Viral Load and Replicative Capacity in Liver Tissue and Blood Leukocytes.Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues.New therapeutic perspectives in HBV: when to stop NAs.Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response.Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analoguesTreatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Hepatitis B: Working Towards a Cure.Monotherapy for hepatitis B infection: a review of treatment options.Pharmacotherapeutic options for hepatitis B.Basis of HBV persistence and new treatment options.Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy.When can we stop nucleoside analogues in patients with chronic hepatitis B?Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion.Sustained Off-Treatment Response After Discontinuation of Long-Term Nucleos(t)ide Analogue Treatment in HBeAg-Seronegative Hepatitis B: A Case Series.Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon.Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study.Long-term lamivudine therapy in chronic hepatitis B.Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.Loss of HBsAg and antiviral treatment: from basics to clinical significance.Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.
P2860
Q26740323-24889769-5D4D-4B38-8C45-DE353D90F122Q26752475-9FD0E5A4-0FD1-4AC6-91F7-D0335FB57FBBQ26781990-296032A6-B426-48C2-BBAA-C66E6EC15618Q26995814-62037425-7C32-4095-85F6-BAC0AD964916Q27020938-0A1EC4F4-5DA1-48CD-BF0E-4F29C8BCF080Q28072483-D36CF361-7938-4EC8-885E-2BBED23ADA6BQ30235028-C01E157A-4C3C-4A4D-8901-19EBB82F6C5AQ30487002-4B5F2AF6-A2A5-44AA-8839-1C1DC6B319EDQ32182914-CDDF89C1-1FEB-4CBB-B80B-DE6C1363D9FEQ33686951-A160F024-47A8-45BB-BBF2-3656EE3AD169Q34501660-9E3B434A-D43A-4FF4-B138-E3D1020FBA9CQ35231805-148123AC-31B7-4C64-8591-C20B20F26E0CQ35628610-CB6807AC-0542-4AC6-9D16-1587D3C2C5B9Q35866293-3CD44186-D9D4-4885-B848-95617F40D19FQ35961444-19C92F8F-CD03-47A0-97F5-C2DDA2F880B1Q37417340-E0246B15-C65B-4F76-A0B3-54C1F5351101Q37620833-A2E26A71-0489-48BA-86B0-AB7AB3F07A67Q38174265-A908DAF7-63F3-4975-A681-11C36C20162AQ38177851-D38A5E5F-4C01-4338-B279-0ABA30BE0FB7Q38223364-CB4B8D89-D0FC-4E7F-B661-1CA0C135F5E4Q38224440-3DEE696A-C749-4922-ADAE-C3B9552B8D5EQ38238547-1C887DFA-63B0-4C9D-A672-46D4BAF42154Q38543596-93817D8D-DD7E-4BC8-A7E3-649EC52FF968Q38566984-8250BF4F-238C-4501-AB68-8B5E2EE6C96FQ38594605-EE109B0E-F618-4522-8E7B-A91810222B9FQ38631076-34602B97-600A-4056-A1D3-BFD81E7F5469Q38982082-7F70223E-FB85-4542-88C1-5AA072AD1A93Q38999610-F4A9797D-3F32-4E21-BA7A-A41D689052BDQ39067306-93976E69-2E1A-40C5-B756-5E0B304C5B8DQ39069309-79522D6A-4D6B-4BCB-8249-00A1117E7111Q40088040-3B543D6A-18AE-45E9-9963-4F6C1CB1DA03Q40189344-1B904B8D-63D6-4EF7-8576-C70002BEEDD5Q40280136-4F2B2737-1D77-4E65-94E2-01BE5C27AC43Q40335324-D99A59EE-435F-40E7-AF92-6DC16197B088Q40361006-FF11DBFA-59FF-459B-8E27-A3CAB2290FFEQ40423977-E313D7F4-0628-4B0F-AD4E-434E117837F0Q40668632-9AF8F439-33DF-4BD1-A9D1-05DA98974AC6Q41121379-B543023A-EE2B-4CEE-B3FA-C089E0CA08DFQ42235230-0A6708AE-FCEE-4A1E-AE72-C02D87AABCC1Q42236065-47C5AE4C-1C76-495D-AC8C-13671ADDE976
P2860
Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Sustained responses and loss o ...... -term treatment with adefovir.
@en
Sustained responses and loss o ...... -term treatment with adefovir.
@nl
type
label
Sustained responses and loss o ...... -term treatment with adefovir.
@en
Sustained responses and loss o ...... -term treatment with adefovir.
@nl
prefLabel
Sustained responses and loss o ...... -term treatment with adefovir.
@en
Sustained responses and loss o ...... -term treatment with adefovir.
@nl
P2093
P1433
P1476
Sustained responses and loss o ...... -term treatment with adefovir.
@en
P2093
Dimitrios Vassilopoulos
Emilia Hadziyannis
Irene Rapti
Stephanos J Hadziyannis
Vassilios Sevastianos
P304
629-636.e1
P356
10.1053/J.GASTRO.2012.05.039
P407
P577
2012-05-31T00:00:00Z